1. Product advantages
High purity, all above 98.5%, no impurities after dissolution
We will test each batch to ensure quality
OEM and private brand services designed for free
Various cap colors available
We can also provide MT1 peptide powder
2. Factory advantages
Professional research team
More than 5 doctors in high-tech R&D laboratories
More than 1000 m2 of factory production line to ensure stable supply
More than 1200 factories to manufacture products and control quality
3. Service advantages
24-hour online service
Track package information and update it for customers
Professional sales team
Accept small order service
Redelivery service if detained by customs

Ravuconazole (BMS-207147; ER-30346) is an oral triazole antifungal drug that can effectively and broad-spectrumly inhibit fungi.
Related categories
Signal pathways>>Anti infection>>Fungi
Research field>>Infection
Target points
Fungal [1]
In vitro studies have shown that Ravuconazole exhibits broad-spectrum activity against a wide range of fungi, including Candida, Trichosporon beigelii, C. neoformans, and A. fumigatus. The range of MIC90 is 0.025 to 0.39 mg/mL Ravuconazoles showed relatively high activity levels against three types of Candida species, with MICs ranging from 0.05 to 0.39 mg/mL Ravuconazoleshows on T Mentaglophytes, T. Rubrum, M. Gypseum has good activity. And M The MIC of Canis is 0.05 to 0.39 mg/mL [1]. Ravuconazole is about 2 to 4 times more potent than itraconazole, and its activity against yeast is about 40 times higher than fluconazole. Ravuconazole and itraconazole have inhibitory effects on most Aspergillus strains, fighting against half of the isolated strains, and their activity is acaricidal. Ravuconazole and itraconazole have activity against most transparent hyphae, skin fungi, and skin fungi, but do not have bactericidal effects, and have no activity against Sporothrix schenckii and Zygomycetes [2].
The maximum concentration of Ravuconazole in plasma and the area under the concentration time curve of Ravuconazole have good linearity in the dose range of 2 to 40mg/kg body weight in vivo studies. Compared with control treatment, Ravuconazole at a dose of 2.5 mg/kg significantly delayed mortality Ravuconazole has also shown substantial therapeutic effects on systemic cryptococcosis [1]. Compared with the number of CFUs in the control lungs, Ravuconazole significantly reduced the number of CFUs in the lungs. In the experimental model of oral candidiasis in rats, Ravuconazole significantly reduced the number of CFUs in oral swabs compared to the control group, and was more effective than Itraconazole and as effective as Fluconazole [3].
Animal experimental mice [1] Ravuconazole was prepared in 0.5% CMC. C with 10% DMSO. New mold 3 was grown on an SDA plate at 30 ℃ for 48 hours, and an attacking organism was prepared in sterile saline solution. Infected mice via tail vein (age, 5 weeks; n=10). Ravuconazole oral administration, 0.2mL per dose, twice daily for 5 consecutive days, starting from 1 hour after infection